{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:30:40Z","timestamp":1793115040279,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","award":["G2201268: Management of Urinary Tract Infections by Community Pharmacists"],"award-info":[{"award-number":["G2201268: Management of Urinary Tract Infections by Community Pharmacists"]}],"id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Newcastle"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pharmacist prescribing has been introduced internationally to improve timely access to treatment in primary care. For uncomplicated urinary tract infections, pharmacist-led services report favourable outcomes, however, the evidence base remains limited by small sample sizes and heterogenous study designs. Large-scale evaluations are needed to better understand pharmacist management practices and prescribing outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore pharmacist management practices for uncomplicated urinary tract infections in community pharmacy settings, including the effectiveness and safety of pharmacist prescribing and variation in clinical outcomes by antibiotic type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data from the PATH-UTI cohort study were analysed across community pharmacies in New South Wales and the Australian Capital Territory. The trial included an initial two-month feasibility pilot followed by a 10-month main study period (July 2023\u2013May 2024). Women aged 18\u201365\u00a0years presenting with symptoms consistent with an uncomplicated urinary tract infection were assessed and managed by trained pharmacists using a structured clinical management protocol aligned with national guidelines. Consultation data were routinely recorded during the pharmacy visit, and patient-reported outcomes were collected by follow-up survey 7\u00a0days later. The primary outcome was self-reported complete symptom resolution at 7-day follow-up. Secondary outcomes included antibiotic prescribing rates, patient reported adherence, referrals, and patient reported adverse events. Differences in symptom resolution by antibiotic type were assessed using a chi-square test of independence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 18,143 consultations were recorded, with 14,680 follow-up surveys (81.0%) completed. Antibiotics were supplied in 92.6% of consultations, most commonly trimethoprim (95.5%). Complete symptom resolution at 7\u00a0days was reported by 79.4% of patients. A further 17.9% reported partial symptom improvement. There was no statistically significant difference in effectiveness across the three antibiotics (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u20093.88,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14). Referrals to a general practitioner or emergency department occurred in 6.9% of cases. Self-reported adverse events were documented in 5.0% of patients, predominantly mild gastrointestinal side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacist prescribing for uncomplicated urinary tract infections achieved symptom resolution rates comparable to previous pharmacy- and physician-led studies. Low rates of adverse events and complications, and strong adherence to the clinical management protocol were also observed. These results suggest that structured, protocol-based pharmacist prescribing for uncomplicated urinary tract infections can support safe and effective management in primary care, with the potential to improve access to treatment and help manage demand on general practice.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registration<\/jats:italic>\n                      : Retrospectively registered: ACTRN 12623000882628.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02226-9","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:39:07Z","timestamp":1790141947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathway to Access UTI Management (PATH-UTI): evaluating pharmacist prescribing and management practices for uncomplicated urinary tract infections in community pharmacy in New South Wales and the Australian Capital Territory, Australia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1612-7422","authenticated-orcid":false,"given":"Mitchell","family":"Budden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Martinez-Mardones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom I.","family":"Benrimoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dineen-Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"5","key":"2226_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hpm.3678","volume":"38","author":"S Downie","year":"2023","unstructured":"Downie S, Walsh J, Kirk-Brown A, et al. How can scope of practice be described and conceptualised in medical and health professions? A systematic review for scoping and content analysis. Int J Health Plann Manag. 2023;38(5):1184\u2013211. https:\/\/doi.org\/10.1002\/hpm.3678.","journal-title":"Int J Health Plann Manag"},{"key":"2226_CR2","unstructured":"Pharmacy Guild of Australia. Scope of Practice of Community Pharmacists in Australia. 2023. https:\/\/www.guild.org.au\/data\/assets\/pdf_file\/0023\/106178\/scope-of-practice-2025.pdf. Accessed 05 Sept 2025."},{"key":"2226_CR3","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/JMDH.S279243","volume":"13","author":"C Hays","year":"2020","unstructured":"Hays C, Sparrow M, Taylor S, et al. Pharmacists\u2019 \u201cFull scope of practice\u201d: Knowledge, attitudes and practices of rural and remote australian pharmacists. J Multidiscip Healthc. 2020;13:1781\u20139. https:\/\/doi.org\/10.2147\/JMDH.S279243.","journal-title":"J Multidiscip Healthc"},{"key":"2226_CR4","unstructured":"Health and Care Professions Council. Scope of Practice. 2024. https:\/\/www.hcpc-uk.org\/standards\/meeting-our-standards\/scope-of-practice\/. Accessed 10 Feb 2026."},{"issue":"3","key":"2226_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1467-9566.2008.01142.x","volume":"31","author":"MC Weiss","year":"2009","unstructured":"Weiss MC, Sutton J. The changing nature of prescribing: pharmacists as prescribers and challenges to medical dominance. Sociol Health Illn. 2009;31(3):406\u201321. https:\/\/doi.org\/10.1111\/j.1467-9566.2008.01142.x.","journal-title":"Sociol Health Illn"},{"key":"2226_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-330","volume":"11","author":"S Bhanbhro","year":"2011","unstructured":"Bhanbhro S, Drennan V, Grant R, et al. Assessing the contribution of prescribing in primary care by nurses and professionals allied to medicine: a systematic review of literature. BMC Health Serv Res. 2011;11:330. https:\/\/doi.org\/10.1186\/1472-6963-11-330.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.2042-7174.2011.00183.x","volume":"19","author":"S Latter","year":"2011","unstructured":"Latter S, Blenkinsopp A. Non-medical prescribing: current and future contribution of pharmacists and nurses. Int J Pharm Pract. 2011;19(6):381\u20132. https:\/\/doi.org\/10.1111\/j.2042-7174.2011.00183.x.","journal-title":"Int J Pharm Pract"},{"key":"2226_CR8","unstructured":"Emmerton L, Marriott J, Bessell T, et al. Pharmacists and prescribing rights: review of international developments. J Pharm Pharm Sci. 2005. https:\/\/sites.ualberta.ca\/~csps\/JPPS8(2)\/L.Emmerton\/pharmacists.pdf. Accessed 10 March 2025."},{"issue":"6","key":"2226_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ijpp.12557","volume":"27","author":"M Zhou","year":"2019","unstructured":"Zhou M, Desborough J, Parkinson A, et al. Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. Int J Pharm Pract. 2019;27(6):479\u201389. https:\/\/doi.org\/10.1111\/ijpp.12557.","journal-title":"Int J Pharm Pract"},{"key":"2226_CR10","unstructured":"New Zealand Ministry of Health. Pharmacy Action Plan 2016 to 2020. 2020. https:\/\/www.health.govt.nz\/publication\/pharmacy-action-plan-2016-2020. Accessed 13 Aug 2023."},{"issue":"11","key":"2226_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/2042098617723312","volume":"8","author":"R Raghunandan","year":"2017","unstructured":"Raghunandan R, Tordoff J, Smith A. Non-medical prescribing in New Zealand: an overview of prescribing rights, service delivery models and training. Ther Adv Drug Saf. 2017;8(11):349\u201360. https:\/\/doi.org\/10.1177\/2042098617723312.","journal-title":"Ther Adv Drug Saf"},{"key":"2226_CR12","unstructured":"Pharmacy Council of New Zealand- 2013 Annual Report. 2013. https:\/\/pharmacycouncil.org.nz\/wp-content\/uploads\/2021\/03\/Annual-Report-2013-web.pdf. Accessed 20 Jan 2026."},{"issue":"11","key":"2226_CR13","doi-asserted-by":"publisher","first-page":"e2341408","DOI":"10.1001\/jamanetworkopen.2023.41408","volume":"6","author":"DL Dixon","year":"2023","unstructured":"Dixon DL, Johnston K, Patterson J, et al. Cost-effectiveness of pharmacist prescribing for managing hypertension in the United States. JAMA Netw Open. 2023;6(11):e2341408. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.41408.","journal-title":"JAMA Netw Open"},{"key":"2226_CR14","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"issue":"1","key":"2226_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3821\/1913-701X-145.1.17","volume":"145","author":"MR Law","year":"2012","unstructured":"Law MR, Ma T, Fisher J, et al. Independent pharmacist prescribing in Canada. Can Pharm J (Ott). 2012;145(1):17\u201323. https:\/\/doi.org\/10.3821\/1913-701X-145.1.17.","journal-title":"Can Pharm J (Ott)"},{"key":"2226_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-138","volume":"12","author":"M Courtenay","year":"2012","unstructured":"Courtenay M, Carey N, Stenner K. An overiew of non medical prescribing across one strategic health authority: a questionnaire survey. BMC Health Serv Res. 2012;12:138. https:\/\/doi.org\/10.1186\/1472-6963-12-138.","journal-title":"BMC Health Serv Res"},{"key":"2226_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/ejhpharm-2012-000189","volume":"19","author":"W Baqir","year":"2012","unstructured":"Baqir W, Miller D, Richardson G. A brief history of pharmacist prescribing in the UK. Eur J Hosp Pharm. 2012;19:487\u20138. https:\/\/doi.org\/10.1136\/ejhpharm-2012-000189.","journal-title":"Eur J Hosp Pharm"},{"issue":"11","key":"2226_CR18","doi-asserted-by":"publisher","first-page":"CD011227","DOI":"10.1002\/14651858.CD011227.pub2","volume":"11","author":"G Weeks","year":"2016","unstructured":"Weeks G, Geroge J, Maclure K, et al. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. Cochrane Database Syst Rev. 2016;11(11):CD011227. https:\/\/doi.org\/10.1002\/14651858.CD011227.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2226_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.sapharm.2024.01.006","volume":"20","author":"RL Walpola","year":"2024","unstructured":"Walpola RL, Issakhany D, Gisev N, et al. The accessibility of pharmacist prescribing and impacts on medicines access: a systematic review. Res Social Adm Pharm. 2024;20(5):475\u201386. https:\/\/doi.org\/10.1016\/j.sapharm.2024.01.006.","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"2226_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1017\/S1463423617000925","volume":"19","author":"F Stewart","year":"2018","unstructured":"Stewart F, Caldwell G, Cassells K, et al. Building capacity in primary care: the implementation of a novel \u201cPharmacy First\u201d scheme for the management of UTI, impetigo and COPD exacerbation. Prim Health Care Res Dev. 2018;19(6):531\u201341. https:\/\/doi.org\/10.1017\/S1463423617000925.","journal-title":"Prim Health Care Res Dev"},{"issue":"2","key":"2226_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2146\/ajhp150349","volume":"74","author":"LM Guirguis","year":"2017","unstructured":"Guirguis LM, Hughes CA, Makowsky MJ, et al. Survey of pharmacist prescribing practices in Alberta. Am J Health Syst Pharm. 2017;74(2):62\u20139. https:\/\/doi.org\/10.2146\/ajhp150349.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"2226_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11096-023-01679-6","volume":"46","author":"A Swart","year":"2024","unstructured":"Swart A, Benrimoj SI, Dineen-Griffin S. The clinical and economic evidence of the management of urinary tract infections by community pharmacists in women aged 16 to 65 years: a systematic review. Int J Clin Pharm. 2024;46(3):574\u201389. https:\/\/doi.org\/10.1007\/s11096-023-01679-6.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2226_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/1715163521999417","volume":"154","author":"JH Wu","year":"2021","unstructured":"Wu JH, Khalid F, Langford BJ, et al. Community pharmacist prescribing of antimicrobials: a systematic review from an antimicrobial stewardship perspective. Can Pharm J Rev Pharm Can. 2021;154(3):179\u201392. https:\/\/doi.org\/10.1177\/1715163521999417.","journal-title":"Can Pharm J Rev Pharm Can"},{"issue":"5","key":"2226_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/1715163518781175","volume":"151","author":"NP Beahm","year":"2018","unstructured":"Beahm NP, Smyth DJ, Tsuyuki RT. Outcomes of urinary tract infection management by pharmacists (RxOUTMAP): a study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community. Can Pharm J. 2018;151(5):305\u201314. https:\/\/doi.org\/10.1177\/1715163518781175.","journal-title":"Can Pharm J"},{"key":"2226_CR25","unstructured":"NSW Health. Pharmacy reform to expand community health care. 2022. https:\/\/www.health.nsw.gov.au\/news\/Pages\/20221113_00.aspx. Accessed 25 May 2024."},{"key":"2226_CR26","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s11096-024-01768-0","volume":"46","author":"M Budden","year":"2024","unstructured":"Budden M, Gilbertson D, Chung S, et al. Clinical management protocols for community pharmacist-led management of urinary tract infections: a review of the grey literature and quality appraisal. Int J Clin Pharm. 2024;46:1256\u201367. https:\/\/doi.org\/10.1007\/s11096-024-01768-0.","journal-title":"Int J Clin Pharm"},{"key":"2226_CR27","unstructured":"Nissen L, Lau E, Spinks J. The management of urinary tract infections by community pharmacists: A state-wide trial: urinary tract infection pharmacy pilot-Queensland (Outcome Report). 2022. https:\/\/eprints.qut.edu.au\/232923\/8\/UTIPP_Q_Final_Report_2022_QUT_for_publication.pdf. Accessed 02 Aug 2023."},{"key":"2226_CR28","unstructured":"NSW Health. NSW Government makes UTI pharmacy trial permanent. 2024. https:\/\/www.health.nsw.gov.au\/news\/Pages\/20240514_01.aspx. Accessed 20 June 2024."},{"key":"2226_CR29","unstructured":"Pharmacy Guild of Australia. Victorian Scope of Practice: community pharmacist program. 2025. https:\/\/www.guild.org.au\/guild-branches\/vic\/victorian-community-pharmacist-statewide-pilot. Accessed 26 March 2026."},{"key":"2226_CR30","unstructured":"Pharmacy Guild of Australia. The role of community pharmacy in primary health care: scope of practice- state & territory progress. 2025. https:\/\/www.guild.org.au\/programs\/scope-of-practice. Accessed 02 Nov 2025."},{"issue":"4","key":"2226_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ijpp\/riaf127","volume":"34","author":"W Shahin","year":"2026","unstructured":"Shahin W, Dunkley K, Wang K, et al. Australian community pharmacists\u2019 views and preparedness to provide a UTI management service. Int J Pharm Pract. 2026;34(4):382\u20139. https:\/\/doi.org\/10.1093\/ijpp\/riaf127.","journal-title":"Int J Pharm Pract"},{"key":"2226_CR32","unstructured":"Prince Edward Island Government. Regulated health professions act pharmacist and pharmacy technician regulations. 2024. https:\/\/www.princeedwardisland.ca\/sites\/default\/files\/legislation\/r10-1-07-regulated_health_professions_act_pharmacist_and_pharmacy_technician_regulations.pdf. Accessed 01 July 2024."},{"key":"2226_CR33","unstructured":"Ontario College of Pharmacists. Assessment & prescribing algorithm for uncomplicated urinary tract infection (cystitis). 2021. https:\/\/ocpinfo.com\/wp-content\/uploads\/2025\/05\/assessment-prescribing-algorithm-urinary-tract-infection-english.pdf. Accessed 20 May 2023."},{"key":"2226_CR34","unstructured":"Canadian Pharmacists Association. How can you help your patients with an uncomplicated UTI? 2021. https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/education-practice-resources\/Uncomplicated_UTI.pdf. Accessed 20 May 2023."},{"key":"2226_CR35","unstructured":"Canadian Pharmacists Association. Pharmacists' Scope of Practice in Canada. 2023. https:\/\/www.pharmacists.ca\/advocacy\/scope-of-practice\/. Accessed 10 April 2025."},{"issue":"5","key":"2226_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1715163517723036","volume":"50","author":"NP Beahm","year":"2017","unstructured":"Beahm NP, Nicolle LE, Bursey A, et al. The assessment and management of urinary tract infections in adults: guidelines for pharmacists. Can Pharm J (Ott). 2017;50(5):298\u2013305. https:\/\/doi.org\/10.1177\/1715163517723036.","journal-title":"Can Pharm J (Ott)"},{"issue":"1","key":"2226_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08476-0","volume":"25","author":"A Piraux","year":"2024","unstructured":"Piraux A, Parot-Schinkel E, Hamel JF, et al. Efficacy of a pharmacist care protocol to manage uncomplicated female cystitis in community pharmacies: an open-label, multicenter, randomized, controlled, cluster study: the PharmaCyst\u2019 protocol. Trials. 2024;25(1):654. https:\/\/doi.org\/10.1186\/s13063-024-08476-0.","journal-title":"Trials"},{"key":"2226_CR38","unstructured":"Government of Ireland: Department of Health. Expert taskforce to support the expansion of the role of pharmacy final report. 2024. https:\/\/www.gov.ie\/en\/department-of-health\/publications\/expert-taskforce-to-support-the-expansion-of-the-role-of-pharmacy-final-report\/. Accessed 09 Sept 2024."},{"key":"2226_CR39","unstructured":"Best Practice Journal. Urinary tract infections (UTIs)- an overview of lower UTI management in adults. 2021. https:\/\/bpac.org.nz\/2021\/docs\/uti.pdf. Accessed 20 May 2023."},{"key":"2226_CR40","unstructured":"Federal Office of Public Health (FOPH). Simplified provision of List B medicinal products. 2019. https:\/\/www.bag.admin.ch\/en\/simplified-provision-of-list-b-medicinal-products. Accessed 12 Dec 2025."},{"key":"2226_CR41","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 160: Management of suspected bacterial lower urinary tract infection in adult women: A national clinical guideline. 2020. https:\/\/www.sign.ac.uk\/media\/1766\/sign-160-uti-0-1_web-version.pdf. Accessed 20 May 2023."},{"key":"2226_CR42","unstructured":"NHS Coastal West Sussex Clinical Commissioning Group. Antibiotic guidelines for the management of infection in primary care 2013. 2012. https:\/\/sussexcds.co.uk\/wp-content\/uploads\/2019\/10\/CWS_Antibiotic_Guidelines_for_the_managemen_to_infection_in_primary_care_2013.pdf. Accessed 20 May 2023."},{"key":"2226_CR43","unstructured":"East Midlands Academic Health Science Network. Evaluation of the treatment of adult women under 65 years presenting with symptoms of uncomplicated urinary tract infections in community pharmacy using home-based urinalysis testing. 2020. https:\/\/emahsn.org.uk\/images\/Digital_UTI_Pathway_Evaluation_-_Final_v270720.pdf. Accessed 20 May 2023."},{"key":"2226_CR44","unstructured":"National Institute for Health and Care Excellence (NICE). UTI (lower): antimicrobial prescribing. 2022. https:\/\/www.nice.org.uk\/guidance\/ng109\/resources\/visual-summary-pdf-6544021069. Accessed 20 May 2023."},{"key":"2226_CR45","unstructured":"Public Health England. Diagnosis of urinary tract infections: Quick reference tool for primary care: for consultation and local adaptation. 2020. https:\/\/assets.publishing.service.gov.uk\/media\/5beac5a3ed915d6a283ef9f9\/Report_of_UTI_diagnostic_flowchart_public_consultation_final_12.11.18.pdf. Accessed 20 May 2023."},{"key":"2226_CR46","unstructured":"NHS Guidance Resources: Pharmacy First Scotland- Urinary tract infections (UTI). 2020. https:\/\/www.nss.nhs.scot\/publications\/pharmacy-first-scotland-urinary-tract-infection-uti\/. Accessed 20 May 2023."},{"key":"2226_CR47","unstructured":"National Services Scotland. (2020). Pharmacy First Scotland- Urinary Tract Infection (UTI). 2020. https:\/\/www.nss.nhs.scot\/publications\/pharmacy-first-scotland-urinary-tract-infection-uti\/. Accessed 20 May 2023."},{"issue":"1","key":"2226_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf466","volume":"81","author":"E Mantzourani","year":"2025","unstructured":"Mantzourani E, Ahmed H, Evans A, et al. A national pilot community pharmacy-led urinary tract infection service: a clinical and patient-reported outcomes from 9077 consultations. J Antimicrob Chemother. 2025;81(1):dkaf466. https:\/\/doi.org\/10.1093\/jac\/dkaf466.","journal-title":"J Antimicrob Chemother"},{"key":"2226_CR49","unstructured":"Kentucky Board of Pharmacy. Acute, uncomplicated urinary tract infection treatment protocol. 2019. https:\/\/pharmacy.ky.gov\/Documents\/ACUTE,%20UNCOMPLICATED%20URINARY%20TRACT%20INFECTION%20TREATMENT%20PROTOCOL%20Approved%20March%2027%202019%20Modified%209.17.2025.pdf. Accessed 19 Nov 2025."},{"key":"2226_CR50","unstructured":"Virginia Board of Pharmacy. Pharmacist protocol for testing and initiating treatment for suspected acute uncomplicated lower urinary tract infection in women. 2023. https:\/\/www.dhp.virginia.gov\/media\/dhpweb\/doc\/pharmacy\/protocols\/UTICombined.pdf. Accessed 12 Feb 2024."},{"key":"2226_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2026.07.004","volume":"9","author":"V Garcia-Cardenas","year":"2026","unstructured":"Garcia-Cardenas V, Frommer MS, Martinez-Mardones F, et al. Towards a shared language for pharmacists prescribing: why terminology matters. Res Social Adm Pharm. 2026;9:S1551-7411. https:\/\/doi.org\/10.1016\/j.sapharm.2026.07.004.","journal-title":"Res Social Adm Pharm"},{"key":"2226_CR52","unstructured":"NSW Health. Expanded scope services- accessing care at your local pharmacy. 2025. https:\/\/www.health.nsw.gov.au\/pharmaceutical\/Pages\/services.aspx. Accessed 20 Jan 2026."},{"key":"2226_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2025.110979","volume":"149","author":"V Chisari","year":"2025","unstructured":"Chisari V, Benson H, Benrimoj SI, et al. Pharmacist-prescribed contraception using clinical protocols: a review of the grey literature. Contraception. 2025;149:110979. https:\/\/doi.org\/10.1016\/j.contraception.2025.110979.","journal-title":"Contraception"},{"key":"2226_CR54","unstructured":"Dineen-Griffin S, Martinez Mardones F, Benrimoj SI, et al. Management of uncomplicated urinary tract infections by community pharmacists: Evaluation of PATH-UTI \u2013 Final report. 2025. College of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, in collaboration with The George Institute for Global Health; University of New South Wales; Hunter Medical Research Institute; University of Technology Sydney; Westmead Hospital; Rural Doctors Network NSW; and Charles Sturt University. https:\/\/www.newcastle.edu.au\/__data\/assets\/pdf_file\/0004\/1131691\/Evaluation-of-PATH-UTI-Final-Report-2026_FINAL.pdf. Accessed 01 June 2026."},{"key":"2226_CR55","unstructured":"Dineen-Griffin S, Martinez Mardones F, Benrimoj SI, et al. Resupply of Oral Contraception by Community Pharmacists: Evaluation of PATH-OC \u2013 Final report. 2026. College of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, in collaboration with The George Institute for Global Health; University of New South Wales; Hunter Medical Research Institute; and University of Technology Sydney. https:\/\/www.newcastle.edu.au\/__data\/assets\/pdf_file\/0004\/1131682\/Evaluation-of-PATH-OC-Final-Report-2026_FINAL.pdf. Accessed 01 June 2026."},{"key":"2226_CR56","unstructured":"Docusign. 2026. https:\/\/www.docusign.com\/en-au. Accessed 10 Feb 2026."},{"key":"2226_CR57","unstructured":"Health Direct. ACT Health. 2019. https:\/\/www.healthdirect.gov.au\/partners\/act-health. Accessed 20 Aug 2026."},{"key":"2226_CR58","unstructured":"Australian Government Department of Health, Disability and Ageing. Modified Monash Model. 2025. https:\/\/www.health.gov.au\/topics\/rural-health-workforce\/classifications\/mmm. Accessed 20 June 2025."},{"key":"2226_CR59","unstructured":"The George Institute for Global Health (TGI). About us. 2026. https:\/\/www.georgeinstitute.org\/about-us. Accessed 20 Jan 2026."},{"key":"2226_CR60","unstructured":"Australasian College of Pharmacy. Uncomplicated cystitis treatment course (UTI pharmacist training). 2023. https:\/\/www.acp.edu.au\/education\/short-courses\/uti-training\/. Accessed 15 Nov 2025."},{"key":"2226_CR61","unstructured":"Pharmaceutical Society of Australia. Managing uncomplicated cystitis (UTI)- ALL but VIC. 2025. https:\/\/my.psa.org.au\/s\/training-plan\/a11RF000005suC1\/managing-uncomplicated-cystitis-uti-all-but-vic. Accessed 10 Dec 2025."},{"key":"2226_CR62","unstructured":"Therapeutic Guidelines. Acute Cystitis in adults [published 2019 June; amended 2025 March] In: Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https:\/\/www.tg.org.au\/. Accessed 20 May 2023."},{"key":"2226_CR63","unstructured":"Therapeutic Guidelines. Antibiotic prescribing in primary care: Therapeutic Guidelines summary table 2019. 2019. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2020-11\/therapeutic_guidelines_-_antibiotic_prescribing_in_primary_care_free_table.pdf. Accessed 20 May 2023."},{"issue":"3","key":"2226_CR64","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3122\/jabfm.2023.230312R1","volume":"37","author":"AM Cole","year":"2024","unstructured":"Cole AM, Keppel GA, Baldwin LM, et al. Implementation strategies used by facilitators to improve control of cardiovascular risk factors in primary care. J Am Board Fam Med. 2024;37(3):444\u201354. https:\/\/doi.org\/10.3122\/jabfm.2023.230312R1.","journal-title":"J Am Board Fam Med"},{"key":"2226_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s43058-023-00470-y","volume":"4","author":"KF Sutton","year":"2023","unstructured":"Sutton KF, Richman EL, Rees JR, et al. Implementing practice facilitation in research: how facilitators spend their time guiding practices to improve blood pressure control. Implement Sci Commun. 2023;4:89. https:\/\/doi.org\/10.1186\/s43058-023-00470-y.","journal-title":"Implement Sci Commun"},{"issue":"20","key":"2226_CR66","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/jama.287.20.2701","volume":"287","author":"S Bent","year":"2002","unstructured":"Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):2701\u201310. https:\/\/doi.org\/10.1001\/jama.287.20.2701.","journal-title":"JAMA"},{"key":"2226_CR67","unstructured":"MedAdvisor. 2026. https:\/\/www.medadvisor.com.au\/Home\/Landing. Accessed 10 Feb 2026."},{"key":"2226_CR68","unstructured":"Australian New Zealand Clinical Trials Registry (ANZCTR). Trial Review. 2023. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=385721&isReview=true. Accessed 20 Aug 2026."},{"issue":"1","key":"2226_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa010","volume":"2","author":"T Thornley","year":"2020","unstructured":"Thornley T, Kirkdale CL, Beech E, et al. Evaluation of a community pharmacy-led test-and-treat service for women with uncomplicated lower urinary tract infection in England. JAC Antimicrob Resist. 2020;2(1):dlaa010. https:\/\/doi.org\/10.1093\/jacamr\/dlaa010.","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"2226_CR70","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.sapharm.2021.07.003","volume":"18","author":"D St\u00e4mpfli","year":"2022","unstructured":"St\u00e4mpfli D, Winkler BA, Vilei SB, et al. Assessment of minor health disorders with decision tree-based triage in community pharmacies. Res Social Adm Pharm. 2022;18(5):2867\u201373. https:\/\/doi.org\/10.1016\/j.sapharm.2021.07.003.","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"2226_CR71","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3138\/jammi-2020-0047","volume":"6","author":"NP Beahm","year":"2021","unstructured":"Beahm NP, Smyth DJ, Tsuyuki RT. Antimicrobial utilization and stewardship in patients with uncomplicated urinary tract infections managed by pharmacists in the community: a sub-study of the RxOUTMAP trial. J Assoc Med Microbiol Infect Dis Can. 2021;6(3):205\u201312. https:\/\/doi.org\/10.3138\/jammi-2020-0047.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"issue":"20","key":"2226_CR72","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","volume":"167","author":"K Gupta","year":"2007","unstructured":"Gupta K, Hooton TM, Roberts PL, et al. Short-Course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007;167(20):2207\u201312. https:\/\/doi.org\/10.1001\/archinte.167.20.2207.","journal-title":"Arch Intern Med"},{"key":"2226_CR73","doi-asserted-by":"publisher","unstructured":"Koh SWC, Ng TSM, VWK L, et al. Antibiotic treatment failure of uncomplicated urinary tract infections in primary care. Antimicrob Resist Infect Control. 2023;12(1):73. https:\/\/doi.org\/10.1186\/s13756-023-01282-4.","DOI":"10.1186\/s13756-023-01282-4"},{"key":"2226_CR74","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2147\/TCRM.S334886","volume":"17","author":"MQ Alanazi","year":"2021","unstructured":"Alanazi MQ. Clinical efficacy and cost analysis of antibiotics for treatment of uncomplicated urinary tract infections in the emergency department of a tertiary hospital in Saudi Arabia. Ther Clin Risk Manag. 2021;17:1209\u201317. https:\/\/doi.org\/10.2147\/TCRM.S334886.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"2226_CR75","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s11606-024-09029-6","volume":"40","author":"DL Fromer","year":"2025","unstructured":"Fromer DL, Luck ME, Cheng WY, et al. Risk factors for empiric treatment failure in US female outpatients with uncomplicated urinary tract infection: an observational study. J Gen Intern Med. 2025;40(4):862\u201370. https:\/\/doi.org\/10.1007\/s11606-024-09029-6.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"2226_CR76","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/jac\/48.6.895","volume":"48","author":"RA Lawrenson","year":"2001","unstructured":"Lawrenson RA, Logie JW. Antibiotic failure in the treatment of urinary tract infections in young women. J Antimicrob Chemother. 2001;48(6):895\u2013901. https:\/\/doi.org\/10.1093\/jac\/48.6.895.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2226_CR77","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/JU.0000000000003268.10","volume":"209","author":"E Dixon","year":"2023","unstructured":"Dixon E, Grove E, Caron A, et al. Natural history of recurrent UTI: poor resolution rates without preventative approaches. J Urol. 2023;209(4):e1\u20131197. https:\/\/doi.org\/10.1097\/JU.0000000000003268.10.","journal-title":"J Urol"},{"issue":"746","key":"2226_CR78","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.3399\/BJGP.2024.0015","volume":"74","author":"L Sanyaolu","year":"2024","unstructured":"Sanyaolu L, Best V, Cannings-John R, et al. Recurrent urinary tract infections and prophylactic antibiotic use in women: a cross-sectional study in primary care. Br J Gen Pract. 2024;74(746):e619\u201327. https:\/\/doi.org\/10.3399\/BJGP.2024.0015.","journal-title":"Br J Gen Pract"},{"key":"2226_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001209.pub2","author":"X Albert","year":"2004","unstructured":"Albert X, Huertas I, Pereir\u00f3 II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004. https:\/\/doi.org\/10.1002\/14651858.CD001209.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2226_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad561","volume":"10","author":"HL Zhang","year":"2023","unstructured":"Zhang HL, Perez R, Krishnan J, et al. Risk factors for recurrence of community-onset urinary tract infections caused by extended-spectrum cephalosporin-resistant enterobacterales. Open Forum Infect Dis. 2023;10(12):ofad561. https:\/\/doi.org\/10.1093\/ofid\/ofad561.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2226_CR81","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPV.0000000000000550","volume":"24","author":"L Brubaker","year":"2018","unstructured":"Brubaker L, Carberry C, Nardos R, et al. American urogynecologic society best-practice statement: recurrent urinary tract infection in adult women. Female Pelvic Med Reconstr Surg. 2018;24(5):321\u201335. https:\/\/doi.org\/10.1097\/SPV.0000000000000550.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"5","key":"2226_CR82","doi-asserted-by":"publisher","first-page":"e1101","DOI":"10.1093\/infdis\/jiae331","volume":"230","author":"BK Ackerson","year":"2024","unstructured":"Ackerson BK, Tartof SY, Chen LH, et al. Risk factors for recurrent urinary tract infections among women in a large integrated health care organization in the United States. J Infect Dis. 2024;230(5):e1101\u201311. https:\/\/doi.org\/10.1093\/infdis\/jiae331.","journal-title":"J Infect Dis"},{"key":"2226_CR83","unstructured":"Australian Commission on Safety and Quality in Health Care. AURA 2023: fifth Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2023. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2023-11\/aura_2023_fifth_australian_report_on_antimicrobial_use_and_resistance_in_human_health.pdf. Accessed 20 May 2024."},{"issue":"6","key":"2226_CR84","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/jep.13340","volume":"26","author":"A Davey","year":"2020","unstructured":"Davey A, Tapley A, Mulquiney K, et al. Management of urinary tract infection by early-career general practitioners in Australia. J Eval Clin Pract. 2020;26(6):1703\u201310. https:\/\/doi.org\/10.1111\/jep.13340.","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"2226_CR85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s15010-020-01512-6","volume":"49","author":"Z Peng","year":"2021","unstructured":"Peng Z, Hayen A, Hall J, et al. Microbiology testing and antibiotic treatment for urinary tract infections in general practice: a nationwide observational study. Infection. 2021;49(2):249\u201355. https:\/\/doi.org\/10.1007\/s15010-020-01512-6.","journal-title":"Infection"},{"issue":"1","key":"2226_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116207","volume":"10","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Karagiannis AKA, Nakouti T, et al. Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10(1):e0116207. https:\/\/doi.org\/10.1371\/journal.pone.0116207.","journal-title":"PLoS ONE"},{"issue":"9","key":"2226_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291050","volume":"18","author":"BA Almomani","year":"2023","unstructured":"Almomani BA, Hijazi BM, Al-Husein BA, et al. Adherence and utilization of short-term antibiotics: randomized controlled study. PLoS ONE. 2023;18(9):e0291050. https:\/\/doi.org\/10.1371\/journal.pone.0291050.","journal-title":"PLoS ONE"},{"issue":"1","key":"2226_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ewjm.176.1.51","volume":"176","author":"T Jancel","year":"2002","unstructured":"Jancel T, Dudas V. Management of uncomplicated urinary tract infections. West J Med. 2002;176(1):51\u20135. https:\/\/doi.org\/10.1136\/ewjm.176.1.51.","journal-title":"West J Med"},{"key":"2226_CR89","unstructured":"Hind C. NHS Grampian project: treating uncomplicated lower urinary tract infection in community pharmacy. 2018. https:\/\/pharmaceutical-journal.com\/article\/research\/nhs-grampian-project-treating-uncomplicated-lower-urinary-tract-infection-in-community-pharmacy. Accessed 20 May 2023."},{"issue":"3","key":"2226_CR90","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/ijpp\/riaf009","volume":"33","author":"P Stehlik","year":"2025","unstructured":"Stehlik P, Moles R, Jones M, et al. Community pharmacists\u2019 referrals to general practice with suspected need of antibiotics: an Australian cross-sectional pilot study. Int J Pharm Pract. 2025;33(3):256\u201361. https:\/\/doi.org\/10.1093\/ijpp\/riaf009.","journal-title":"Int J Pharm Pract"},{"issue":"4","key":"2226_CR91","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.sapharm.2021.05.002","volume":"18","author":"A Mallinder","year":"2022","unstructured":"Mallinder A, Martini N. Exploring community pharmacists\u2019 clinical decision-making using think aloud and protocol analysis. Res Social Adm Pharm. 2022;18(4):2606\u201314. https:\/\/doi.org\/10.1016\/j.sapharm.2021.05.002.","journal-title":"Res Social Adm Pharm"},{"issue":"8","key":"2226_CR92","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/cid\/ciab637","volume":"74","author":"AM Butler","year":"2022","unstructured":"Butler AM, Durkin MJ, Keller MR, et al. Association of adverse events with antibiotic treatment for urinary tract infection. Clin Infect Dis. 2022;74(8):1408\u201318. https:\/\/doi.org\/10.1093\/cid\/ciab637.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2226_CR93","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ajog.2016.07.040","volume":"215","author":"JR Price","year":"2016","unstructured":"Price JR, Guran LA, Gregory WT, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;215(5):548\u201360. https:\/\/doi.org\/10.1016\/j.ajog.2016.07.040.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2226_CR94","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11096-016-0415-1","volume":"39","author":"NJ Gauld","year":"2017","unstructured":"Gauld NJ, Zeng ISL, Ikram RB, et al. Antibiotic treatment of women with uncomplicated cystitis before and after allowing pharmacist-supply of trimethoprim. Int J Clin Pharm. 2017;39(1):165\u201372. https:\/\/doi.org\/10.1007\/s11096-016-0415-1.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2226_CR95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/AJN.0000000000000014","volume":"125","author":"B Capili","year":"2025","unstructured":"Capili B, Anastasi JK. Pragmatic clinical trials and real-world evidence: an introduction. Am J Nurs. 2025;125(2):56\u20138. https:\/\/doi.org\/10.1097\/AJN.0000000000000014.","journal-title":"Am J Nurs"},{"issue":"5","key":"2226_CR96","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41433-021-01897-0","volume":"36","author":"A Miroshnychenko","year":"2022","unstructured":"Miroshnychenko A, Zeraatkar D, Phillips MR, et al. Cohort studies investigating the effects of exposures: key principles that impact the credibility of the results. Eye (Lond). 2022;36(5):905\u20136. https:\/\/doi.org\/10.1038\/s41433-021-01897-0.","journal-title":"Eye (Lond)"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02226-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:03:54Z","timestamp":1790186634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":96,"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02226-9","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the University of Newcastle HREC (H-2023-0035), the NSW Health Population Health Services Research Ethics Committee (2024\/ETH01457\/2023.37) and the Services Australia Executive Committee (RMS3171). The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623000882628).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided informed consent for their de-identified data to be used in publications arising from the study. Participants who did not provide consent for publication of their data were excluded from the results presented.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}